Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-438 |
| Synonyms | |
| Therapy Description |
ABBV-438 is an antibody-drug conjugate (ADC) targeting CD38, which potentially induces killing of CD38-expressing tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-438 | ABBV438|ABBV 438 | CD38 Antibody 22 | ABBV-438 is an antibody-drug conjugate (ADC) targeting CD38, which potentially induces killing of CD38-expressing tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07409246 | Phase I | ABBV-438 | A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) | Recruiting | USA | ISR | 2 |